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The tumour microenvironment is shaped by the interac-
tion of tumour cells with a variety of “non” malignant
cellular and acellular components. It is the secretion of
cytokines, chemokines, metabolites and other mediators in
the tumour stroma that shapes the natural evolution of
cancer. Whereas the tumour strives to promote an immu-
nosuppressive environment to limit anti-tumour immune
response, infiltrating immune cells aim to control tumour
growth. The balance between these two conflicting inter-
ests shapes the immune contexture of cancer and ulti-
mately patient prognosis. In an effort to characterize the
role played by macrophages, we have developed an in vitro
system using human pancreatic tumour cell lines and a
human monocyte-macrophage leukemic cell line (ThP1).
We have investigated the immunosuppressive properties
of pancreatic cancer cell lines and how the immune prop-
erties of macrophages are influenced by the tumour super-
natant in vitro. We have applied our findings to a clinically
relevant murine model of pancreatic cancer. We found
that, despite some heterogeneity, the profile of MIA-
PACA-2, BxPC3 and PANC-1, included IL-8, MCP-1, SCF
and VEGF secretion. Not surprisingly, when ThP1 cell
were cultured in the presence of increasing concentrations
of tumour supernatant and stimulated with LPS, we
observed a significant downregulation of their ability to
produce cytokines associated with an M1 profile (e.g. IL-6,
IL-12p70, IL-23, TNF-a). However, ThP1 also failed to
display an M2 profile; IL-10 and IL-1ra were similarly
downregulated. ThP1 stimulated with LPS in the presence
of tumour supernatant also had impaired secretion of a
number of other cytokines such as IL-18, MIP-1a and
MIP-1b and MCP-1. In contrast, they appeared to main-
tain secretion of VEGF and IL-7. Next we investigated
how the immune stimulant IMM-101, an immunothera-
peutic agent comprising heat-killed whole cell Mycobac-
terium obuense, might be able to shift this anergic
phenotype. IMM-101 is currently under clinical evaluation
in two Phase II clinical trials in pancreatic (EudraCT num-
ber 2010-022757-42) and colorectal cancer (EudraCT
number 2011-003958-85). We found that despite the pre-
sence of tumour supernatant, macrophages stimulated
with IMM-101 retained the ability to secrete the full range
of cytokines and we did not observe the impairment
reported after LPS stimulation. We believe the immunolo-
gical properties of IMM-101 make this a potential candi-
date for successful immunotherapy.
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